Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices 76855 

ACTION: Notice of request for public 

comments. 

SUMMARY: In accordance with the 

provisions of the Paperwork Reduction 

Act of 1995, the U.S. International Trade 

Commission (Commission or USITC) 

hereby gives notice that it plans to 

submit a request for approval of a 

questionnaire to the Office of 

Management and Budget (OMB) for 

review and requests public comment on 

its draft proposed collection. 

DATES: To ensure that the Commission 

will consider your comments, it must 

receive them no later than 60 days after 

publication of this notice in the Federal 

Register. 

ADDRESSES: All Commission offices are 

in the U.S. International Trade 

Commission Building, 500 E Street SW, 

Washington, DC. 

FOR FURTHER INFORMATION CONTACT: 

Please direct all questions to the project 

team via email at sa.emissions@

usitc.gov or via phone to Shova KC at 

202–205–2234. 

The public record for this 

investigation may be viewed on the 

Commission’s electronic docket (EDIS) 

at https://edis.usitc.gov. General 

information concerning the Commission 

may be obtained by accessing its 

internet address (https://www.usitc.gov). 

Hearing-impaired individuals are 

advised that information on this matter 

can be obtained by contacting the TDD 

terminal on 202–205–1810. 

SUPPLEMENTARY INFORMATION: 

The information requested by the 

questionnaire is for use by the 

Commission in connection with 

Investigation No. 332–598, Greenhouse 

Gas Emissions Intensities of the U.S. 

Steel and Aluminum Industries at the 

Product Level, instituted under the 

authority of section 332(g) of the Tariff 

Act of 1930 (19 U.S.C. 1332(g)). This 

investigation and report were requested 

by the United States Trade 

Representative (USTR) on June 5, 2023. 

This investigation was initiated on July 

5, 2023, and the notice of investigation 

was published in the Federal Register 

on July 10, 2023 (88 FR 43633). The 

Commission will deliver its report to 

USTR by January 28, 2025. 

As stated in the notice of 

investigation, the USTR requested that 

the Commission’s report include 

greenhouse gas (GHG) emissions 

intensities of covered steel and 

aluminum products produced in the 

United States. Such information is not 

available in the requested specificity 

from governmental or other public 

sources. The Commission indicated in 

its notice of investigation that it will 

need to obtain much of such data and 

information through a survey. The 

survey will assist the Commission in 

developing, as requested, GHG 

emissions intensities which reflect 

scope 1 and scope 2 GHG emissions 

associated with production of covered 

steel and aluminum products produced 

at facilities in the United States, as well 

as certain scope 3 GHG emissions 

associated with the upstream 

intermediate inputs into these products. 

Summary of Proposal: The 

Commission intends to submit the 

following draft information collection 

plan to OMB and invites public 

comment. 

(1) Number of forms submitted: 2. 

(2) Title of forms: Greenhouse Gas 

(GHG) Emissions Intensity 

Questionnaire, Company-level and 

Facility-level. 

(3) Type of request: New. 

(4) Frequency of use: Industry 

questionnaire, single data gathering in 

two-step collection, scheduled for 2024. 

(5) Description of respondents: U.S. 

companies and facilities that produce 

covered steel and aluminum products. 

(6) Estimated number of respondents: 

1,000 companies and 2,500 facilities. 

(7) Estimated total number of hours to 

complete the questionnaire per 

respondent: 1 hour per company, 25 

hours per facility. 

(8) Information obtained from the 

questionnaire will be treated as 

confidential business information by the 

Commission and not disclosed in a 

manner that would reveal the individual 

operations of a business. 

Method of Collection: The proposed 

collection is a two-step data collection. 

First, identified steel and aluminum 

companies will be sent a letter and/or 

email with a link and individual 

questionnaire token for accessing the 

online questionnaire’s section 1.1. This 

step involves the company providing 

information (including contact 

information) on the facilities it owns 

that produce covered steel and/or 

aluminum products. Once submitted by 

the company, each facility identified 

will receive a questionnaire token and 

link to complete the remainder of the 

questionnaire applicable to that facility. 

Respondents will be able to download a 

PDF version of the questionnaire to see 

all questions in their entirety, but this 

PDF will not be accepted as a 

submission. 

Request for Comments: Comments are 

invited on (1) the elements of the draft 

questionnaire; (2) whether the proposed 

collection of information is necessary; 

(3) the accuracy of the agency’s estimate 

of the burden of the proposed 

information collection (4) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(5) ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

The draft questionnaire and other 

supplementary documents may be 

downloaded from the USITC website at 

https://www.usitc.gov/saemissions. 

Any comments on the draft 

questionnaire should be sent via email 

at sa.emissions@usitc.gov. Comments 

submitted in response to this notice will 

be summarized and included in the 

request for OMB approval of this 

information collection; they will also 

become a matter of public record. As 

such, proprietary or confidential 

business information should not be 

submitted as part of comments on the 

draft questionnaire. 

By order of the Commission. 

Issued: November 2, 2023. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2023–24572 Filed 11–6–23; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1289] 

Importer of Controlled Substances 

Application: Groff NA Hemplex LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Groff NA Hemplex LLC has 

applied to be registered as an importer 

of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before December 7, 2023. Such 

persons may also file a written request 

for a hearing on the application on or 

before December 7, 2023. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 


khammond on DSKJM1Z7X2PROD with NOTICES
76856 Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices 

1Effective December 2, 2022, the Medical 

Marijuana and Cannabidiol Research Expansion 

Act, Pub. L. 117–215, 136 Stat. 2257 (2022) 

(Marijuana Research Amendments or MRA), 

amended the Controlled Substances Act (CSA) and 

other statutes. Relevant to this matter, the MRA 

redesignated 21 U.S.C. 823(f), cited in the OSC, as 

21 U.S.C. 823(g)(1). Accordingly, this Decision cites 

to the current designation, 21 U.S.C. 823(g)(1), and 

to the MRA-amended CSA throughout. 

2By letter dated March 14, 2022, Respondent 

requested a hearing. RFAAX 15, at 1. On May 16, 

2022, Respondent withdrew his hearing request and 

Chief Administrative Law Judge John J. Mulrooney, 

II, issued an Order Terminating Proceedings. 

RFAAX 16; RFAAX 17. 

3On June 6, 2021, Respondent emailed the DI a 

document titled ‘‘Controlled Drug Inventory 5–25– 

2021.’’ Declaration, at 4; see also RFAAX 6. 

4As noted by the DI, the most recent invoice 

indicated that Respondent himself purchased 100 

tablets of 2 mg alprazolam under his own DEA 

registration; all of the other invoices for the 

controlled substance purchases in question showed 

that the controlled substances were shipped to 

another practitioner at the Pet Hospital, G.K. Id. at 

2–3; see also RFAAX 2, at 66; RFAAX 8, at 1; 

RFAAX 9, at 3. Respondent also admitted that his 

wife paid for all of the controlled substances 

ordered for the Pet Hospital. Declaration, at 3. 

5Though unable to produce dispensing records 

for the controlled substances in question, 

Respondent was able to produce dispensing records 

for other controlled substances. Id. at 3; see also 

RFAAX 4. According to the DI, these other 

dispensing records were commingled with records 

of other practitioners, including G.K., and because 

the records lacked detail, the DI was unable to 

determine which controlled substances had been 

dispensed by Respondent. Id. Because there were 

no records showing the disposition of the 

oxycodone, alprazolam, or zolpidem in question, 

the DI was unable to confirm whether the drugs had 

been purchased for a legitimate medical purpose; 

moreover, there was no evidence that Respondent 

had contacted any law enforcement agency to report 

the diversion of any oxycodone, alprazolam, or 

zolpidem. Declaration, at 3. 

6Respondent admitted to DI that he observed 

G.K. receiving a shipment of alprazolam in 2019; 

specifically, Respondent observed G.K. meet a 

delivery driver outside the Pet Hospital who gave 

G.K. several boxes that G.K. then placed in his 

personal vehicle. Id. Respondent stated that he then 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on September 19, 2023, 

Groff NA Hemplex LLC, 100 Redco 

Avenue, Suite A, Red Lion, 

Pennsylvania 17356–1436, applied to be 

registered as an importer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug code Schedule 

Marihuana Extract .................................................................................................................................................... 7350 I 

Marihuana ................................................................................................................................................................ 7360 I 

Tetrahydrocannabinols ............................................................................................................................................ 7370 I 

The company plans to import the 

listed controlled substances in bulk 

form to manufacture research grade 

material for clinical trial studies. 

Several types of Marihuana Extract 

compounds are listed under drug code 

7350. No other activities for these drug 

codes are authorized for this 

registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Claude Redd, 

Acting Deputy Assistant Administrator. 

[FR Doc. 2023–24575 Filed 11–6–23; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Jagjit Kaleka, D.V.M.; Decision and 

Order 

On February 25, 2022, the Drug 

Enforcement Administration (DEA or 

Government) issued an Order to Show 

Cause (OSC) to Jagjit Kaleka, D.V.M. 

(Respondent), of Mauston, Wisconsin. 

Request for Final Agency Action 

(RFAA), Government Exhibit (RFAAX) 

13, at 1, 5. The OSC proposed the 

revocation of Respondent’s DEA 

Certificate of Registration (registration), 

Control No. AK7830640, alleging that 

Respondent has ‘‘committed such acts 

as would render [his] registration 

inconsistent with the public interest.’’ 

Id. at 1, 2 (citing 21 U.S.C. 824(a)(4), 

823(g)(1) 1). 

The Agency makes the following 

findings of fact based on the 

uncontroverted evidence submitted by 

the Government in its RFAA dated April 

6, 2023.2

I. Findings of Fact 

According to the Declaration of a DEA 

Diversion Investigator (the DI), 

Respondent was the owner of and a 

veterinarian at Mauston Pet Hospital 

(the Pet Hospital). RFAA, Declaration of 

Diversion Investigator (Declaration), at 

2. From June 21, 2019, through February 

22, 2021, the Pet Hospital purchased 

500 tablets of 10 mg oxycodone 

(Schedule II), 1000 tablets of 2 mg 

alprazolam (Schedule IV), and 100 

tablets of 5 mg zolpidem (Schedule IV). 

Id.; see also RFAAX 2; RFAAX 9. On 

June 8, 2021, the DI served a Notice of 

Inspection at the Pet Hospital, and 

Respondent consented to an inspection 

of the premises. Declaration, at 2; see 

also RFAAX 7. Prior to the inspection, 

the DI asked Respondent to take an 

inventory of all controlled substances at 

the Pet Hospital,3 and on the day of the 

inspection, the DI asked Respondent to 

produce a biennial inventory, which 

Respondent was unable to produce. 

Declaration, at 2, 4. 

During the inspection, Respondent 

denied personally ordering the 

controlled substances in question, 

namely, oxycodone, alprazolam, and 

zolpidem. Declaration, at 2.4 The DI 

explained that despite the Pet Hospital’s 

purchases, ‘‘[n]one of these drugs could 

be located on the premises and there 

were no records showing that the drugs 

had been dispensed, lost, stolen, or 

otherwise disposed of.’’ Id. at 2, 3.5

Further, ‘‘[t]hough Respondent denied 

knowledge that [G.K., another 

practitioner at the Pet Hospital,] had 

been using the Pet Hospital’s account to 

purchase and obtain controlled 

substances for other than a legitimate 

medical purpose in the usual course of 

veterinary practice, Respondent 

[admitted that he] was aware of at least 

one incident during which [G.K.] 

purchased and received alprazolam.’’ 

Id.6 Notably, Respondent admitted that 


khammond on DSKJM1Z7X2PROD with NOTICES